A practical reference on peptide hormone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-08 and is reviewed periodically as new material appears.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Although the term was coined in the late 1980s one of the first retroactively recognized examples of a killer application is the VisiCalc spreadsheet, released in 1979 for the Apple II. Because it was not released for other computers for 12 months, people spent US$100 (equivalent to $400 in 2025) for the software first, then $2,000 to $10,000 (equivalent to $9,000 to $44,000) on the requisite Apple II. Byte wrote in 1980, "VisiCalc is the first program available on a microcomputer that has been responsible for sales of entire systems", and Creative Computing's VisiCalc review is subtitled "reason enough for owning a computer". Others also chose to develop software, such as EasyWriter, for the Apple II first because of its higher sales, helping Apple defeat rivals Commodore International and Tandy Corporation. The co-creator of WordStar, Seymour Rubinstein, argued that the honor of the first killer app should go to that popular word processor, given that it came out a year before VisiCalc and that it gave a reason for people to buy a computer. However, whereas WordStar could be considered an incremental improvement (albeit a large one) over smart typewriters like the IBM Electronic Selectric Composer, VisiCalc, with its ability to instantly recalculate rows and columns, introduced an entirely new paradigm and capability unavailable on larger computers. Lotus 1-2-3 similarly benefited sales of the IBM PC. Noting that computer purchasers did not want PC compatibility as much as compatibility with certain PC software, InfoWorld suggested "let's tell it like it is.
== References == Aldose reductase inhibitor for treatment of diabetic complications. Prepn (stereo unspec): M. Kurono, et al., EP 193415; eidem, US 4740517 (1986, 1988 both to Sanwa) Prepn of isomers: T. Yamaguchi et al., Arzneim.-Forsch. 44, 344 (1994) Pharmacological profile: K. Mizuno et al. in Current Concepts of Aldose Reductase and Its Inhibitions, N. Sakamoto et al., Eds. (Elsevier, Amsterdam, 1990) pp 89–96. Configuration and crystal structure of complex with aldose reductase: M. Oka et al., J. Med. Chem. 43, 2479 (2000). Clinical efficacy in diabetic peripheral neuropathy: N. Hotta et al., Diabetes Care 24, 1776 (2001). Clinical suppression of sorbitol accumulation in erythrocytes of diabetic patients: T. Asano et al., J. Diabetes Complications 16, 133 (2002); eidem, ibid. 18, 336 (2004). Review of clinical development: N. Giannoukakis, Curr. Opin. Invest. Drugs 4, 1233-1239 (2003).
There is a difference between the al-Houthi family and the Houthi movement. The movement was called by their opponents and foreign media "Houthis". The name came from the surname of the early leader of the movement, Hussein al-Houthi, who died in 2004. Membership of the group had between 1,000 and 3,000 fighters as of 2005 and between 2,000 and 10,000 fighters as of 2009. In 2010, the Yemen Post claimed that they had over 100,000 fighters. According to Houthi expert Ahmed Al-Bahri, by 2010, the Houthis had a total of 100,000–120,000 followers, including both armed fighters and unarmed loyalists. As of 2015, the group is reported to have attracted new supporters from outside their traditional demographics.
== Law == Charitable lead trust, a form of charitable trust in the United States Community land trust, a housing model Consolidation of Labor Laws, a 1943 Brazilian law (Portuguese: Consolidação das Leis do Trabalho)
Sources: en.wikipedia.org
== History == Willis Carrier, a mechanical engineer working for Buffalo Forge, is credited with inventing modern air conditioning in July 1902. In 1908, the Carrier Air Conditioner Company of America was created as a subsidiary of the Buffalo Forge Company, with Willis Carrier as its vice president. With the onset of World War I in late 1914, the Buffalo Forge Company, where Carrier had been employed for 12 years, decided to confine its activities entirely to manufacturing. The result was that in 1915, Carrier and six other engineers pooled $32,600 to form the Carrier Engineering Corporation. They purchased their first factory in 1920, in Newark, New Jersey. The very next year, Carrier solved a problem that had vexed the Islington Studios (owned by Famous Players–Lasky and then Paramount Pictures) in London -- thick fog coming into the stage set and suspending filming. A pressurized system that cooled air at a rate of "3,500,000 gallons per hour" and then delivered the dehumidified air at the temperature set by a thermostat, kept the interior air clear and camera-ready. In 1955, Carrier merged with Affiliated Gas Equipment, Inc., which owned the Bryant Heater Co., Day & Night Water Heater Co., and Payne Furnace & Supply Co. Carrier Corporation was acquired by United Technologies Corporation (UTC) in July 1979. Prior to the acquisition by UTC, Carrier Corporation was known as the Carrier Air Conditioning Company. International Comfort Products (ICP), headquartered in Lewisburg, Tennessee, was acquired by Carrier in 1999.
=== Rocks === These are asteroids and other non-planetary bodies hollowed out for habitation and usually spun for centrifugal artificial gravity. Rocks (with the exception of those used for secretive purposes) are described as having faster-than-light space drives, and thus can be considered a special form of spaceship. Like Orbitals, they are usually administered by one or more Minds. Rocks do not play a large part in most of the Culture stories, though their use as storage for mothballed military ships (Pittance) and habitats (Phage Rock, one of the founding communities of the Culture) are both key plot points in Excession.
== Further reading == Celebrating the 100th birthday of Professor Endre Mester, M.D., Ph.D. Laser World Enwemeka, CS (2004). "Therapeutic light". Rehab Management. 17 (1): 20–5, 56–7. PMID 14974136. Archived from the original on 2012-10-14.
=== Humanity === Humans uniquely share spiritual attributes with God and the angels above them, love and language, and physical attributes with the animals below them, like having material bodies that experienced emotions and sensations such as lust and pain, as well as physical needs such as hunger and thirst.
=== Susceptible animals === The virus is responsible for a highly transmissible respiratory tract infection in mice, hamsters, guinea pigs, rats, and occasionally marmosets, with infection passing through both air and direct contact routes. Natural infection occurs by way of the respiratory tract. In animal facility airborne transmission can occur over a distance of 5–6 feet as well as through air handling systems. The virus can be detected in mouse colonies worldwide, generally in suckling to young adult mice. A study in France reported antibodies to SeV in 17% of mouse colonies examined. Epizootic infections of mice are usually associated with a high mortality rate, while enzootic disease patterns suggest that the virus is latent and can be cleared over the course of a year. Sub-lethal exposure to SeV can promote long-lasting immunity to further lethal doses of SeV. The virus is immunosuppressive and may predispose to secondary bacterial infections. There are no scientific studies, which were performed using modern detection methods, which would identify SeV as an infectious and decease causative for humans or domestic animals.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.